Our Management Team

Dr Bill (William) Allan, CEO

Bill is an internationally experienced medical devices executive who has held a number of general management and leadership positions with global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and Stryker. He has a strong track record of building businesses and launching new products and has worked in Europe, Africa and North America.

Educated at the University of Edinburgh, University of Capetown and Insead Business School, Bill is a mentor at Cambridge University (Judge) Business School and a council member of ABHI (Association of British Healthcare Industries).


Frank Coombes, CFO

Frank has over 15 years experience in corporate finance, gained both in industry and professional practice. He has held various senior executive finance positions with the “top five” corporate finance consultancies as well as a variety of start-up companies. He has extensive experience of company acquisitions, disposals and fund raising.


Dr John Gleeson, CTO

John was previously Business Development Manager in the Tissue Engineering Research Group in the Royal College of Surgeons in Ireland. He is an inventor of the technologies and a Principal Investigator/Honorary Research Fellow within RCSI, where as head of the Cartilage Advanced Regenerative Therapies (CART) group, he was responsible for over €2.5 million research funding in the fields of Tissue Engineering and Translational Research. He has a PhD in bioengineering from Trinity College Dublin and an MSc in Leadership & Management from RCSI.


Brian Mulcahy, Quality/Regulatory Affairs Manager

Brian brings significant leadership experience in Quality and Regulatory affairs to the team, with more than 10 years experience leading multiple-market Regulatory activities within Pharma/Medtech companies including DiaSorin, Henkel Biomedical and Merck MSD. Brian has extensive executive experience in all aspects of Regulatory Body engagement, including site preparation, documentation compilation & submission, and post market product registration activities.